GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
O

Onconic Therapeutics 476060.KQ · KRW

N/A · KOSDAQ · 🇰🇷 South Korea

Compare

11,610

-0.60%

Close of 9 Nov 2026, in KRW

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in KRW, from our data supplier.

FY2025

Revenue

₩53.39bn

FY2022FY2025

Net income

₩15.78bn

FY2022FY2025

Free cash flow

₩11.09bn

FY2022FY2025

Shareholders' equity

₩72.04bn

FY2022FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022
Revenue₩53.39bn₩14.84bn₩21.06bn₩95.0m
Gross profit₩53.39bn₩14.84bn₩21.06bn₩95.0m
Research and development₩9.72bn₩10.93bn₩15.76bn₩13.18bn
Operating income₩12.62bn−₩4.80bn₩1.57bn−₩14.84bn
Net income₩15.78bn−₩8.09bn₩1.68bn−₩14.43bn
Diluted earnings per share355.12-749.04155.73-1,335.80

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022
Total assets₩75.71bn₩60.91bn₩37.55bn₩30.91bn
Total liabilities₩3.67bn₩4.89bn₩57.24bn₩52.84bn
Debt—₩308.5m₩14.15bn₩12.10bn
Shareholders' equity₩72.04bn₩56.02bn−₩19.69bn−₩21.94bn
Shares outstanding44m11m11m11m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022
Cash from operations₩11.40bn−₩7.84bn₩4.14bn−₩14.96bn
Capital spending−₩302.9m−₩141.3m−₩1.16bn−₩2.58bn
Free cash flow₩11.09bn−₩7.98bn₩2.98bn−₩17.54bn

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue₩24.40bn₩22.98bn₩15.58bn₩19.21bn₩9.43bn₩9.17bn₩8.84bn₩1.99bn
Gross profit₩24.40bn₩22.98bn₩15.58bn₩19.21bn₩9.43bn₩9.17bn——
Operating income₩2.79bn₩4.59bn₩1.61bn₩8.32bn₩1.11bn₩1.58bn₩1.37bn−₩2.35bn
Net income₩3.77bn₩6.42bn₩4.66bn₩9.40bn−₩155.7m₩1.88bn₩5.63bn−₩2.78bn
Diluted earnings per share83.94143.07104.82211.54-14.16172.61520.99-257.29
Cash from operations₩3.72bn₩3.42bn₩1.88bn₩7.79bn₩503.0m₩1.23bn−₩2.23bn−₩5.61bn
Capital spending−₩134.0m−₩40.0m−₩104.0m−₩38.0m——−₩12.0m−₩128.0m
Free cash flow₩3.59bn₩3.38bn₩1.77bn₩7.75bn——−₩2.24bn−₩5.74bn
Total assets₩92.98bn₩87.59bn₩75.71bn₩73.88bn₩63.62bn₩62.57bn₩60.91bn₩33.84bn
Cash and short-term investments——————₩43.00bn₩24.52bn
Debt——————₩119.5m₩163.7m
Shareholders' equity₩85.78bn₩79.52bn₩72.04bn₩68.88bn₩58.98bn₩58.37bn₩56.02bn₩30.40bn

Financial ratios

Data as of 29 Aug 2026

FY2025FY2024FY2023FY2022
Gross margin100.0%100.0%100.0%100.0%
Operating margin23.6%-32.3%7.5%-15618.5%
Net margin29.6%-54.5%8.0%-15191.5%
Return on equity21.9%-14.4%-8.5%65.8%
Return on assets20.8%-13.3%4.5%-46.7%
Revenue growth259.8%-29.5%22064.2%—
Earnings growth-295.0%-581.0%-111.7%—
Current ratio17.62x10.94x0.54x1.06x
Equity ratio95.2%92.0%-52.4%-71.0%
Interest coverage1080.49x-7.22x0.89x-16.41x
R&D as a share of sales18.2%73.7%74.9%13877.2%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue725.2%——

Average margins

Over each period

1 year3 years5 years10 years
Gross margin100.0%100.0%——

Valuation history

At each fiscal year end

FY2025FY2024
Price to earnings55.0-5.5
Price to sales16.33.0

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 4-for-1 split · 10 Oct 2025

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.